#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=The number of males diagnosed with prostate cancer ( PCa ) is increasing all over the world .
1-1	0-3	The	quantity[1]	new[1]	_	_
1-2	4-10	number	quantity[1]	new[1]	_	_
1-3	11-13	of	quantity[1]	new[1]	_	_
1-4	14-19	males	quantity[1]|person	new[1]|new	_	_
1-5	20-29	diagnosed	_	_	_	_
1-6	30-34	with	_	_	_	_
1-7	35-43	prostate	place|abstract[4]	new|new[4]	appos|coref	1-10[0_4]|4-20
1-8	44-50	cancer	abstract[4]	new[4]	_	_
1-9	51-52	(	_	_	_	_
1-10	53-56	PCa	abstract	giv	coref	2-4[8_0]
1-11	57-58	)	_	_	_	_
1-12	59-61	is	_	_	_	_
1-13	62-72	increasing	_	_	_	_
1-14	73-76	all	_	_	_	_
1-15	77-81	over	_	_	_	_
1-16	82-85	the	place[6]	new[6]	_	_
1-17	86-91	world	place[6]	new[6]	_	_
1-18	92-93	.	_	_	_	_

#Text=Most patients with early-stage PCa can be treated by the appropriate therapy , such as radical prostatectomy or irradiation .
2-1	94-98	Most	person[7]	new[7]	coref	3-19[16_7]
2-2	99-107	patients	person[7]	new[7]	_	_
2-3	108-112	with	person[7]	new[7]	_	_
2-4	113-124	early-stage	person[7]|abstract[8]	new[7]|giv[8]	coref	3-21[17_8]
2-5	125-128	PCa	person[7]|abstract[8]	new[7]|giv[8]	_	_
2-6	129-132	can	_	_	_	_
2-7	133-135	be	_	_	_	_
2-8	136-143	treated	_	_	_	_
2-9	144-146	by	_	_	_	_
2-10	147-150	the	abstract[9]	new[9]	coref	3-6[13_9]
2-11	151-162	appropriate	abstract[9]	new[9]	_	_
2-12	163-170	therapy	abstract[9]	new[9]	_	_
2-13	171-172	,	abstract[9]	new[9]	_	_
2-14	173-177	such	abstract[9]	new[9]	_	_
2-15	178-180	as	abstract[9]	new[9]	_	_
2-16	181-188	radical	abstract[9]|object[10]	new[9]|new[10]	_	_
2-17	189-202	prostatectomy	abstract[9]|object[10]	new[9]|new[10]	_	_
2-18	203-205	or	abstract[9]	new[9]	_	_
2-19	206-217	irradiation	abstract[9]|abstract	new[9]|new	_	_
2-20	218-219	.	_	_	_	_

#Text=On the other hand , androgen deprivation therapy ( ADT ) is the standard systemic therapy given to patients with advanced PCa .
3-1	220-222	On	_	_	_	_
3-2	223-226	the	_	_	_	_
3-3	227-232	other	_	_	_	_
3-4	233-237	hand	_	_	_	_
3-5	238-239	,	_	_	_	_
3-6	240-248	androgen	abstract[13]	giv[13]	coref	3-13[15_13]
3-7	249-260	deprivation	abstract|abstract[13]	new|giv[13]	_	_
3-8	261-268	therapy	abstract[13]	giv[13]	_	_
3-9	269-270	(	_	_	_	_
3-10	271-274	ADT	organization	new	coref	4-1
3-11	275-276	)	_	_	_	_
3-12	277-279	is	_	_	_	_
3-13	280-283	the	abstract[15]	giv[15]	_	_
3-14	284-292	standard	abstract[15]	giv[15]	_	_
3-15	293-301	systemic	abstract[15]	giv[15]	_	_
3-16	302-309	therapy	abstract[15]	giv[15]	_	_
3-17	310-315	given	_	_	_	_
3-18	316-318	to	_	_	_	_
3-19	319-327	patients	person[16]	giv[16]	coref	4-7[20_16]
3-20	328-332	with	person[16]	giv[16]	_	_
3-21	333-341	advanced	person[16]|abstract[17]	giv[16]|giv[17]	coref	4-19[24_17]
3-22	342-345	PCa	person[16]|abstract[17]	giv[16]|giv[17]	_	_
3-23	346-347	.	_	_	_	_

#Text=ADT induces temporary remission , but the majority of patients ( approximately 60 % ) eventually progress to castration-resistant prostate cancer ( CRPC ) , which is associated with a high mortality rate .
4-1	348-351	ADT	event	giv	coref	6-6
4-2	352-359	induces	_	_	_	_
4-3	360-369	temporary	event[19]	new[19]	_	_
4-4	370-379	remission	event[19]	new[19]	_	_
4-5	380-381	,	_	_	_	_
4-6	382-385	but	_	_	_	_
4-7	386-389	the	person[20]	giv[20]	coref	17-32[151_20]
4-8	390-398	majority	person[20]	giv[20]	_	_
4-9	399-401	of	person[20]	giv[20]	_	_
4-10	402-410	patients	person[20]	giv[20]	_	_
4-11	411-412	(	_	_	_	_
4-12	413-426	approximately	quantity[21]	new[21]	_	_
4-13	427-429	60	quantity[21]	new[21]	_	_
4-14	430-431	%	quantity[21]	new[21]	_	_
4-15	432-433	)	_	_	_	_
4-16	434-444	eventually	abstract[22]	new[22]	coref	9-2[61_22]
4-17	445-453	progress	abstract[22]	new[22]	_	_
4-18	454-456	to	abstract[22]	new[22]	_	_
4-19	457-477	castration-resistant	abstract[22]|abstract[24]	new[22]|giv[24]	coref	5-4[0_24]
4-20	478-486	prostate	abstract[22]|place|abstract[24]	new[22]|giv|giv[24]	coref	11-37
4-21	487-493	cancer	abstract[22]|abstract[24]	new[22]|giv[24]	_	_
4-22	494-495	(	_	_	_	_
4-23	496-500	CRPC	object	new	coref	8-16
4-24	501-502	)	_	_	_	_
4-25	503-504	,	_	_	_	_
4-26	505-510	which	_	_	_	_
4-27	511-513	is	_	_	_	_
4-28	514-524	associated	_	_	_	_
4-29	525-529	with	_	_	_	_
4-30	530-531	a	abstract[27]	new[27]	_	_
4-31	532-536	high	abstract[27]	new[27]	_	_
4-32	537-546	mortality	event|abstract[27]	new|new[27]	_	_
4-33	547-551	rate	abstract[27]	new[27]	_	_
4-34	552-553	.	_	_	_	_

#Text=Generally , well-differentiated PCa cells are androgen-dependent , i. e. , androgen receptor ( AR ) signaling regulates cell cycle and differentiation .
5-1	554-563	Generally	_	_	_	_
5-2	564-565	,	_	_	_	_
5-3	566-585	well-differentiated	object[29]	new[29]	coref	5-7[0_29]
5-4	586-589	PCa	substance|object[29]	giv|new[29]	coref	6-16
5-5	590-595	cells	object[29]	new[29]	_	_
5-6	596-599	are	_	_	_	_
5-7	600-618	androgen-dependent	object	giv	coref	6-12[44_0]
5-8	619-620	,	_	_	_	_
5-9	621-623	i.	_	_	_	_
5-10	624-626	e.	_	_	_	_
5-11	627-628	,	_	_	_	_
5-12	629-637	androgen	substance|abstract[32]	new|new[32]	appos	5-15[0_32]
5-13	638-646	receptor	abstract[32]	new[32]	_	_
5-14	647-648	(	_	_	_	_
5-15	649-651	AR	abstract	giv	coref	6-3
5-16	652-653	)	_	_	_	_
5-17	654-663	signaling	abstract	new	_	_
5-18	664-673	regulates	_	_	_	_
5-19	674-678	cell	place|abstract[36]	new|new[36]	_	_
5-20	679-684	cycle	abstract[36]	new[36]	_	_
5-21	685-688	and	_	_	_	_
5-22	689-704	differentiation	event	new	_	_
5-23	705-706	.	_	_	_	_

#Text=Loss of AR signaling after ADT triggers androgen-independent outgrowth , generating poorly differentiated , uncontrollable PCa cells .
6-1	707-711	Loss	person	new	_	_
6-2	712-714	of	_	_	_	_
6-3	715-717	AR	abstract	giv	coref	8-29
6-4	718-727	signaling	_	_	_	_
6-5	728-733	after	_	_	_	_
6-6	734-737	ADT	abstract	giv	coref	7-8
6-7	738-746	triggers	_	_	_	_
6-8	747-767	androgen-independent	person|abstract[42]	new|new[42]	_	_
6-9	768-777	outgrowth	abstract[42]	new[42]	_	_
6-10	778-779	,	_	_	_	_
6-11	780-790	generating	_	_	_	_
6-12	791-797	poorly	object[44]	giv[44]	coref	7-2[46_44]
6-13	798-812	differentiated	object[44]	giv[44]	_	_
6-14	813-814	,	object[44]	giv[44]	_	_
6-15	815-829	uncontrollable	object[44]	giv[44]	_	_
6-16	830-833	PCa	abstract|object[44]	giv|giv[44]	coref	7-2
6-17	834-839	cells	object[44]	giv[44]	_	_
6-18	840-841	.	_	_	_	_

#Text=Once PCa cells lose their sensitivity to ADT , effective therapies are limited .
7-1	842-846	Once	_	_	_	_
7-2	847-850	PCa	substance|object[46]	giv|giv[46]	ana|coref	7-5[0_46]|13-25
7-3	851-856	cells	object[46]	giv[46]	_	_
7-4	857-861	lose	_	_	_	_
7-5	862-867	their	object|abstract[48]	giv|new[48]	coref	17-11[146_0]
7-6	868-879	sensitivity	abstract[48]	new[48]	_	_
7-7	880-882	to	_	_	_	_
7-8	883-886	ADT	abstract	giv	_	_
7-9	887-888	,	_	_	_	_
7-10	889-898	effective	abstract[50]	new[50]	_	_
7-11	899-908	therapies	abstract[50]	new[50]	_	_
7-12	909-912	are	_	_	_	_
7-13	913-920	limited	_	_	_	_
7-14	921-922	.	_	_	_	_

#Text=In the last few years , however , several new options for the treatment of CRPC have been approved , e. g. , the CYP17 inhibitor , the AR antagonist , and the taxane .
8-1	923-925	In	_	_	_	_
8-2	926-929	the	time[51]	new[51]	coref	12-10[97_51]
8-3	930-934	last	time[51]	new[51]	_	_
8-4	935-938	few	time[51]	new[51]	_	_
8-5	939-944	years	time[51]	new[51]	_	_
8-6	945-946	,	_	_	_	_
8-7	947-954	however	_	_	_	_
8-8	955-956	,	_	_	_	_
8-9	957-964	several	abstract[52]	new[52]	_	_
8-10	965-968	new	abstract[52]	new[52]	_	_
8-11	969-976	options	abstract[52]	new[52]	_	_
8-12	977-980	for	abstract[52]	new[52]	_	_
8-13	981-984	the	abstract[52]|abstract[53]	new[52]|new[53]	coref	10-17[0_53]
8-14	985-994	treatment	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-15	995-997	of	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-16	998-1002	CRPC	abstract[52]|abstract[53]|abstract	new[52]|new[53]|giv	coref	17-39
8-17	1003-1007	have	_	_	_	_
8-18	1008-1012	been	_	_	_	_
8-19	1013-1021	approved	_	_	_	_
8-20	1022-1023	,	_	_	_	_
8-21	1024-1026	e.	abstract[55]	new[55]	coref	15-8[127_55]
8-22	1027-1029	g.	abstract[55]	new[55]	_	_
8-23	1030-1031	,	_	_	_	_
8-24	1032-1035	the	abstract[57]	new[57]	_	_
8-25	1036-1041	CYP17	abstract|abstract[57]	new|new[57]	_	_
8-26	1042-1051	inhibitor	abstract[57]	new[57]	_	_
8-27	1052-1053	,	_	_	_	_
8-28	1054-1057	the	person[59]	new[59]	_	_
8-29	1058-1060	AR	abstract|person[59]	giv|new[59]	coref	15-22
8-30	1061-1071	antagonist	person[59]	new[59]	_	_
8-31	1072-1073	,	_	_	_	_
8-32	1074-1077	and	_	_	_	_
8-33	1078-1081	the	substance[60]	new[60]	_	_
8-34	1082-1088	taxane	substance[60]	new[60]	_	_
8-35	1089-1090	.	_	_	_	_

#Text=Despite this progress in the development of new drugs , there is a high medical need for optimizing the sequence and combination of approved drugs .
9-1	1091-1098	Despite	_	_	_	_
9-2	1099-1103	this	abstract[61]	giv[61]	_	_
9-3	1104-1112	progress	abstract[61]	giv[61]	_	_
9-4	1113-1115	in	abstract[61]	giv[61]	_	_
9-5	1116-1119	the	abstract[61]|abstract[62]	giv[61]|new[62]	_	_
9-6	1120-1131	development	abstract[61]|abstract[62]	giv[61]|new[62]	_	_
9-7	1132-1134	of	abstract[61]|abstract[62]	giv[61]|new[62]	_	_
9-8	1135-1138	new	abstract[61]|abstract[62]|substance[63]	giv[61]|new[62]|new[63]	coref	9-24[67_63]
9-9	1139-1144	drugs	abstract[61]|abstract[62]|substance[63]	giv[61]|new[62]|new[63]	_	_
9-10	1145-1146	,	_	_	_	_
9-11	1147-1152	there	_	_	_	_
9-12	1153-1155	is	_	_	_	_
9-13	1156-1157	a	abstract[64]	new[64]	_	_
9-14	1158-1162	high	abstract[64]	new[64]	_	_
9-15	1163-1170	medical	abstract[64]	new[64]	_	_
9-16	1171-1175	need	abstract[64]	new[64]	_	_
9-17	1176-1179	for	_	_	_	_
9-18	1180-1190	optimizing	_	_	_	_
9-19	1191-1194	the	abstract[65]	new[65]	_	_
9-20	1195-1203	sequence	abstract[65]	new[65]	_	_
9-21	1204-1207	and	_	_	_	_
9-22	1208-1219	combination	abstract[66]	new[66]	_	_
9-23	1220-1222	of	abstract[66]	new[66]	_	_
9-24	1223-1231	approved	abstract[66]|substance[67]	new[66]|giv[67]	_	_
9-25	1232-1237	drugs	abstract[66]|substance[67]	new[66]|giv[67]	_	_
9-26	1238-1239	.	_	_	_	_

#Text=Thus , identification of predictive biomarkers may help in the context of personalized medicine to guide treatment decisions , improve clinical outcomes , and prevent unnecessary side effects .
10-1	1240-1244	Thus	_	_	_	_
10-2	1245-1246	,	_	_	_	_
10-3	1247-1261	identification	abstract[68]	new[68]	_	_
10-4	1262-1264	of	abstract[68]	new[68]	_	_
10-5	1265-1275	predictive	abstract[68]|abstract[69]	new[68]|new[69]	_	_
10-6	1276-1286	biomarkers	abstract[68]|abstract[69]	new[68]|new[69]	_	_
10-7	1287-1290	may	_	_	_	_
10-8	1291-1295	help	_	_	_	_
10-9	1296-1298	in	_	_	_	_
10-10	1299-1302	the	abstract[70]	new[70]	_	_
10-11	1303-1310	context	abstract[70]	new[70]	_	_
10-12	1311-1313	of	abstract[70]	new[70]	_	_
10-13	1314-1326	personalized	abstract[70]|abstract[71]	new[70]|new[71]	coref	11-28[0_71]
10-14	1327-1335	medicine	abstract[70]|abstract[71]	new[70]|new[71]	_	_
10-15	1336-1338	to	_	_	_	_
10-16	1339-1344	guide	_	_	_	_
10-17	1345-1354	treatment	abstract|abstract[73]	giv|new[73]	_	_
10-18	1355-1364	decisions	abstract[73]	new[73]	_	_
10-19	1365-1366	,	_	_	_	_
10-20	1367-1374	improve	_	_	_	_
10-21	1375-1383	clinical	abstract[74]	new[74]	_	_
10-22	1384-1392	outcomes	abstract[74]	new[74]	_	_
10-23	1393-1394	,	_	_	_	_
10-24	1395-1398	and	_	_	_	_
10-25	1399-1406	prevent	_	_	_	_
10-26	1407-1418	unnecessary	abstract[75]	new[75]	_	_
10-27	1419-1423	side	abstract[75]	new[75]	_	_
10-28	1424-1431	effects	abstract[75]	new[75]	_	_
10-29	1432-1433	.	_	_	_	_

#Text=Departments of Nephro-Urologic Surgery and Andrology ( Professor Emeritus Yoshiki Sugimura ) and Oncologic Pathology ( Professor Emeritus Taizo Shiraishi ) , Mie University Graduate School of Medicine , organized the semi-closed symposium on Biology of Prostate Gland Ise-Shima .
11-1	1434-1445	Departments	organization	new	appos	11-3[79_0]
11-2	1446-1448	of	_	_	_	_
11-3	1449-1464	Nephro-Urologic	abstract|event[78]|organization[79]	new|new[78]|giv[79]	appos	11-7[82_78]
11-4	1465-1472	Surgery	event[78]|organization[79]	new[78]|giv[79]	_	_
11-5	1473-1476	and	organization[79]	giv[79]	_	_
11-6	1477-1486	Andrology	organization[79]|place	giv[79]|new	_	_
11-7	1487-1488	(	event[82]	giv[82]	_	_
11-8	1489-1498	Professor	person[81]|event[82]	new[81]|giv[82]	appos	11-17[85_81]
11-9	1499-1507	Emeritus	person[81]|event[82]	new[81]|giv[82]	_	_
11-10	1508-1515	Yoshiki	person[81]|event[82]	new[81]|giv[82]	_	_
11-11	1516-1524	Sugimura	person[81]|event[82]	new[81]|giv[82]	_	_
11-12	1525-1526	)	event[82]	giv[82]	_	_
11-13	1527-1530	and	event[82]	giv[82]	_	_
11-14	1531-1540	Oncologic	event[82]|abstract|abstract[84]	giv[82]|new|new[84]	_	_
11-15	1541-1550	Pathology	event[82]|abstract[84]	giv[82]|new[84]	_	_
11-16	1551-1552	(	_	_	_	_
11-17	1553-1562	Professor	person[85]	giv[85]	_	_
11-18	1563-1571	Emeritus	person[85]	giv[85]	_	_
11-19	1572-1577	Taizo	person[85]|abstract	giv[85]|new	_	_
11-20	1578-1587	Shiraishi	person[85]	giv[85]	_	_
11-21	1588-1589	)	_	_	_	_
11-22	1590-1591	,	_	_	_	_
11-23	1592-1595	Mie	person[88]	new[88]	_	_
11-24	1596-1606	University	organization|person[88]	new|new[88]	_	_
11-25	1607-1615	Graduate	person[88]	new[88]	_	_
11-26	1616-1622	School	person[88]	new[88]	_	_
11-27	1623-1625	of	person[88]	new[88]	_	_
11-28	1626-1634	Medicine	person[88]|abstract	new[88]|giv	coref	17-24[149_0]
11-29	1635-1636	,	_	_	_	_
11-30	1637-1646	organized	_	_	_	_
11-31	1647-1650	the	event[90]	new[90]	coref	12-1[95_90]
11-32	1651-1662	semi-closed	event[90]	new[90]	_	_
11-33	1663-1672	symposium	event[90]	new[90]	_	_
11-34	1673-1675	on	event[90]	new[90]	_	_
11-35	1676-1683	Biology	event[90]|abstract[91]	new[90]|new[91]	_	_
11-36	1684-1686	of	event[90]|abstract[91]	new[90]|new[91]	_	_
11-37	1687-1695	Prostate	event[90]|abstract[91]|place|abstract[94]	new[90]|new[91]|giv|new[94]	coref	13-22
11-38	1696-1701	Gland	event[90]|abstract[91]|object|abstract[94]	new[90]|new[91]|new|new[94]	coref	13-21[113_0]
11-39	1702-1711	Ise-Shima	event[90]|abstract[91]|abstract[94]	new[90]|new[91]|new[94]	_	_
11-40	1712-1713	.	_	_	_	_

#Text=This symposium was started in 2002 and was held every four years in 2006 , 2010 , 2014 , and 2018 without any financial support from pharmaceutical companies and chemical industries .
12-1	1714-1718	This	event[95]	giv[95]	coref	13-4[106_95]
12-2	1719-1728	symposium	event[95]	giv[95]	_	_
12-3	1729-1732	was	_	_	_	_
12-4	1733-1740	started	_	_	_	_
12-5	1741-1743	in	_	_	_	_
12-6	1744-1748	2002	time	new	_	_
12-7	1749-1752	and	_	_	_	_
12-8	1753-1756	was	_	_	_	_
12-9	1757-1761	held	_	_	_	_
12-10	1762-1767	every	time[97]	giv[97]	_	_
12-11	1768-1772	four	time[97]	giv[97]	_	_
12-12	1773-1778	years	time[97]	giv[97]	_	_
12-13	1779-1781	in	_	_	_	_
12-14	1782-1786	2006	time[98]	new[98]	_	_
12-15	1787-1788	,	time[98]	new[98]	_	_
12-16	1789-1793	2010	time[98]|time	new[98]|new	_	_
12-17	1794-1795	,	time[98]	new[98]	_	_
12-18	1796-1800	2014	time[98]|time	new[98]|new	_	_
12-19	1801-1802	,	_	_	_	_
12-20	1803-1806	and	_	_	_	_
12-21	1807-1811	2018	time	new	coref	16-13
12-22	1812-1819	without	_	_	_	_
12-23	1820-1823	any	abstract[102]	new[102]	_	_
12-24	1824-1833	financial	abstract[102]	new[102]	_	_
12-25	1834-1841	support	abstract[102]	new[102]	_	_
12-26	1842-1846	from	abstract[102]	new[102]	_	_
12-27	1847-1861	pharmaceutical	abstract[102]|organization[103]	new[102]|new[103]	_	_
12-28	1862-1871	companies	abstract[102]|organization[103]	new[102]|new[103]	_	_
12-29	1872-1875	and	abstract[102]	new[102]	_	_
12-30	1876-1884	chemical	abstract[102]|organization[104]	new[102]|new[104]	_	_
12-31	1885-1895	industries	abstract[102]|organization[104]	new[102]|new[104]	_	_
12-32	1896-1897	.	_	_	_	_

#Text=Each year , the symposium was attended by 40 – 50 Japanese investigators with expertise and interest in biology of the prostate gland and PCa .
13-1	1898-1902	Each	time[105]	new[105]	_	_
13-2	1903-1907	year	time[105]	new[105]	_	_
13-3	1908-1909	,	_	_	_	_
13-4	1910-1913	the	event[106]	giv[106]	coref	14-4[116_106]
13-5	1914-1923	symposium	event[106]	giv[106]	_	_
13-6	1924-1927	was	_	_	_	_
13-7	1928-1936	attended	_	_	_	_
13-8	1937-1939	by	_	_	_	_
13-9	1940-1942	40	person[108]	new[108]	_	_
13-10	1943-1944	–	person[108]	new[108]	_	_
13-11	1945-1947	50	quantity|person[108]	new|new[108]	_	_
13-12	1948-1956	Japanese	person[108]	new[108]	_	_
13-13	1957-1970	investigators	person[108]	new[108]	_	_
13-14	1971-1975	with	person[108]	new[108]	_	_
13-15	1976-1985	expertise	person[108]|abstract	new[108]|new	coref	18-15
13-16	1986-1989	and	person[108]	new[108]	_	_
13-17	1990-1998	interest	person[108]|abstract	new[108]|new	coref	18-17
13-18	1999-2001	in	_	_	_	_
13-19	2002-2009	biology	abstract[111]	new[111]	_	_
13-20	2010-2012	of	abstract[111]	new[111]	_	_
13-21	2013-2016	the	abstract[111]|object[113]	new[111]|giv[113]	_	_
13-22	2017-2025	prostate	abstract[111]|place|object[113]	new[111]|giv|giv[113]	_	_
13-23	2026-2031	gland	abstract[111]|object[113]	new[111]|giv[113]	_	_
13-24	2032-2035	and	abstract[111]	new[111]	_	_
13-25	2036-2039	PCa	abstract[111]|object	new[111]|giv	coref	14-30
13-26	2040-2041	.	_	_	_	_

#Text=The goal of this symposium was to discuss the biological mechanism of the development and progression of prostatic proliferative diseases such as benign prostatic hyperplasia ( BPH ) and PCa .
14-1	2042-2045	The	abstract[115]	new[115]	_	_
14-2	2046-2050	goal	abstract[115]	new[115]	_	_
14-3	2051-2053	of	abstract[115]	new[115]	_	_
14-4	2054-2058	this	abstract[115]|event[116]	new[115]|giv[116]	coref	16-10[140_116]
14-5	2059-2068	symposium	abstract[115]|event[116]	new[115]|giv[116]	_	_
14-6	2069-2072	was	_	_	_	_
14-7	2073-2075	to	_	_	_	_
14-8	2076-2083	discuss	_	_	_	_
14-9	2084-2087	the	abstract[117]	new[117]	_	_
14-10	2088-2098	biological	abstract[117]	new[117]	_	_
14-11	2099-2108	mechanism	abstract[117]	new[117]	_	_
14-12	2109-2111	of	abstract[117]	new[117]	_	_
14-13	2112-2115	the	abstract[117]|abstract[118]	new[117]|new[118]	_	_
14-14	2116-2127	development	abstract[117]|abstract[118]	new[117]|new[118]	_	_
14-15	2128-2131	and	abstract[117]	new[117]	_	_
14-16	2132-2143	progression	abstract[117]|event[119]	new[117]|new[119]	coref	15-25[134_119]
14-17	2144-2146	of	abstract[117]|event[119]	new[117]|new[119]	_	_
14-18	2147-2156	prostatic	abstract[117]|event[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
14-19	2157-2170	proliferative	abstract[117]|event[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
14-20	2171-2179	diseases	abstract[117]|event[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
14-21	2180-2184	such	abstract[117]|event[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
14-22	2185-2187	as	abstract[117]|event[119]|abstract[120]	new[117]|new[119]|new[120]	_	_
14-23	2188-2194	benign	abstract[117]|event[119]|abstract[120]|abstract[122]	new[117]|new[119]|new[120]|new[122]	_	_
14-24	2195-2204	prostatic	abstract[117]|event[119]|abstract[120]|abstract|abstract[122]	new[117]|new[119]|new[120]|new|new[122]	_	_
14-25	2205-2216	hyperplasia	abstract[117]|event[119]|abstract[120]|abstract[122]	new[117]|new[119]|new[120]|new[122]	_	_
14-26	2217-2218	(	_	_	_	_
14-27	2219-2222	BPH	object	new	coref	15-14
14-28	2223-2224	)	_	_	_	_
14-29	2225-2228	and	_	_	_	_
14-30	2229-2232	PCa	abstract	giv	coref	15-20
14-31	2233-2234	.	_	_	_	_

#Text=Several major topic areas were discussed , e. g. , the pathophysiology of BPH , the tumor microenvironment of PCa , AR signaling in PCa progression , and the development of PCa detection and diagnosis .
15-1	2235-2242	Several	abstract[126]	new[126]	_	_
15-2	2243-2248	major	abstract[126]	new[126]	_	_
15-3	2249-2254	topic	abstract|abstract[126]	new|new[126]	_	_
15-4	2255-2260	areas	abstract[126]	new[126]	_	_
15-5	2261-2265	were	_	_	_	_
15-6	2266-2275	discussed	_	_	_	_
15-7	2276-2277	,	_	_	_	_
15-8	2278-2280	e.	abstract[127]	giv[127]	_	_
15-9	2281-2283	g.	abstract[127]	giv[127]	_	_
15-10	2284-2285	,	abstract[127]	giv[127]	_	_
15-11	2286-2289	the	abstract[127]	giv[127]	_	_
15-12	2290-2305	pathophysiology	abstract[127]	giv[127]	_	_
15-13	2306-2308	of	abstract[127]	giv[127]	_	_
15-14	2309-2312	BPH	abstract[127]|abstract	giv[127]|giv	appos	15-16[130_0]
15-15	2313-2314	,	abstract[127]	giv[127]	_	_
15-16	2315-2318	the	abstract[127]|abstract[130]	giv[127]|giv[130]	_	_
15-17	2319-2324	tumor	abstract[127]|abstract|abstract[130]	giv[127]|new|giv[130]	_	_
15-18	2325-2341	microenvironment	abstract[127]|abstract[130]	giv[127]|giv[130]	_	_
15-19	2342-2344	of	abstract[127]|abstract[130]	giv[127]|giv[130]	_	_
15-20	2345-2348	PCa	abstract[127]|abstract[130]|object	giv[127]|giv[130]|giv	coref	15-25
15-21	2349-2350	,	abstract[127]	giv[127]	_	_
15-22	2351-2353	AR	abstract[127]|abstract	giv[127]|giv	_	_
15-23	2354-2363	signaling	abstract[127]	giv[127]	_	_
15-24	2364-2366	in	abstract[127]	giv[127]	_	_
15-25	2367-2370	PCa	abstract[127]|abstract|event[134]	giv[127]|giv|giv[134]	coref	15-32
15-26	2371-2382	progression	abstract[127]|event[134]	giv[127]|giv[134]	_	_
15-27	2383-2384	,	abstract[127]	giv[127]	_	_
15-28	2385-2388	and	abstract[127]	giv[127]	_	_
15-29	2389-2392	the	abstract[127]	giv[127]	_	_
15-30	2393-2404	development	abstract[127]	giv[127]	_	_
15-31	2405-2407	of	abstract[127]	giv[127]	_	_
15-32	2408-2411	PCa	abstract[127]|object|abstract[136]	giv[127]|giv|new[136]	coref	17-12
15-33	2412-2421	detection	abstract[127]|abstract[136]	giv[127]|new[136]	_	_
15-34	2422-2425	and	abstract[127]	giv[127]	_	_
15-35	2426-2435	diagnosis	abstract[127]|event	giv[127]|new	_	_
15-36	2436-2437	.	_	_	_	_

#Text=This Special Issue includes the major topics discussed at the symposium in 2018 .
16-1	2438-2442	This	abstract[138]	new[138]	coref	17-2[142_138]
16-2	2443-2450	Special	abstract[138]	new[138]	_	_
16-3	2451-2456	Issue	abstract[138]	new[138]	_	_
16-4	2457-2465	includes	_	_	_	_
16-5	2466-2469	the	abstract[139]	new[139]	_	_
16-6	2470-2475	major	abstract[139]	new[139]	_	_
16-7	2476-2482	topics	abstract[139]	new[139]	_	_
16-8	2483-2492	discussed	_	_	_	_
16-9	2493-2495	at	_	_	_	_
16-10	2496-2499	the	event[140]	giv[140]	_	_
16-11	2500-2509	symposium	event[140]	giv[140]	_	_
16-12	2510-2512	in	_	_	_	_
16-13	2513-2517	2018	time	giv	_	_
16-14	2518-2519	.	_	_	_	_

#Text=In this Special Issue , we focused on cytobiology of human PCa cells and its clinical applications to develop a major step towards personalized medicine matched to the individual needs of patients with early-stage and advanced PCa and CRPC .
17-1	2520-2522	In	_	_	_	_
17-2	2523-2527	this	abstract[142]	giv[142]	coref	18-4[155_142]
17-3	2528-2535	Special	abstract[142]	giv[142]	_	_
17-4	2536-2541	Issue	abstract[142]	giv[142]	_	_
17-5	2542-2543	,	_	_	_	_
17-6	2544-2546	we	person	acc	ana	18-1
17-7	2547-2554	focused	_	_	_	_
17-8	2555-2557	on	_	_	_	_
17-9	2558-2569	cytobiology	abstract[144]	new[144]	_	_
17-10	2570-2572	of	abstract[144]	new[144]	_	_
17-11	2573-2578	human	abstract[144]|object[146]	new[144]|giv[146]	coref	18-22[162_146]
17-12	2579-2582	PCa	abstract[144]|abstract|object[146]	new[144]|giv|giv[146]	coref	17-34[152_0]
17-13	2583-2588	cells	abstract[144]|object[146]	new[144]|giv[146]	_	_
17-14	2589-2592	and	abstract[144]|object[146]	new[144]|giv[146]	_	_
17-15	2593-2596	its	abstract[144]|object[146]|abstract[147]	new[144]|giv[146]|new[147]	coref	18-26[163_147]
17-16	2597-2605	clinical	abstract[144]|object[146]|abstract[147]	new[144]|giv[146]|new[147]	_	_
17-17	2606-2618	applications	abstract[144]|object[146]|abstract[147]	new[144]|giv[146]|new[147]	_	_
17-18	2619-2621	to	_	_	_	_
17-19	2622-2629	develop	_	_	_	_
17-20	2630-2631	a	abstract[148]	new[148]	_	_
17-21	2632-2637	major	abstract[148]	new[148]	_	_
17-22	2638-2642	step	abstract[148]	new[148]	_	_
17-23	2643-2650	towards	abstract[148]	new[148]	_	_
17-24	2651-2663	personalized	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
17-25	2664-2672	medicine	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
17-26	2673-2680	matched	_	_	_	_
17-27	2681-2683	to	_	_	_	_
17-28	2684-2687	the	abstract[150]	new[150]	_	_
17-29	2688-2698	individual	abstract[150]	new[150]	_	_
17-30	2699-2704	needs	abstract[150]	new[150]	_	_
17-31	2705-2707	of	abstract[150]	new[150]	_	_
17-32	2708-2716	patients	abstract[150]|person[151]	new[150]|giv[151]	_	_
17-33	2717-2721	with	abstract[150]|person[151]	new[150]|giv[151]	_	_
17-34	2722-2733	early-stage	abstract[150]|person[151]|abstract[152]	new[150]|giv[151]|giv[152]	coref	18-23[0_152]
17-35	2734-2737	and	abstract[150]|person[151]|abstract[152]	new[150]|giv[151]|giv[152]	_	_
17-36	2738-2746	advanced	abstract[150]|person[151]|abstract[152]	new[150]|giv[151]|giv[152]	_	_
17-37	2747-2750	PCa	abstract[150]|person[151]|abstract[152]	new[150]|giv[151]|giv[152]	_	_
17-38	2751-2754	and	abstract[150]|person[151]	new[150]|giv[151]	_	_
17-39	2755-2759	CRPC	abstract[150]|person[151]|abstract	new[150]|giv[151]|giv	_	_
17-40	2760-2761	.	_	_	_	_

#Text=We hope that this Special Issue attracts a lot of attention for readers with expertise and interest in the cytobiology of human PCa cells and its clinical applications .
18-1	2762-2764	We	person	giv	_	_
18-2	2765-2769	hope	_	_	_	_
18-3	2770-2774	that	_	_	_	_
18-4	2775-2779	this	abstract[155]	giv[155]	_	_
18-5	2780-2787	Special	abstract[155]	giv[155]	_	_
18-6	2788-2793	Issue	abstract[155]	giv[155]	_	_
18-7	2794-2802	attracts	_	_	_	_
18-8	2803-2804	a	abstract[156]	new[156]	_	_
18-9	2805-2808	lot	abstract[156]	new[156]	_	_
18-10	2809-2811	of	abstract[156]	new[156]	_	_
18-11	2812-2821	attention	abstract[156]	new[156]	_	_
18-12	2822-2825	for	_	_	_	_
18-13	2826-2833	readers	person[157]	new[157]	_	_
18-14	2834-2838	with	person[157]	new[157]	_	_
18-15	2839-2848	expertise	person[157]|abstract	new[157]|giv	_	_
18-16	2849-2852	and	person[157]	new[157]	_	_
18-17	2853-2861	interest	person[157]|abstract	new[157]|giv	_	_
18-18	2862-2864	in	_	_	_	_
18-19	2865-2868	the	abstract[160]	new[160]	_	_
18-20	2869-2880	cytobiology	abstract[160]	new[160]	_	_
18-21	2881-2883	of	abstract[160]	new[160]	_	_
18-22	2884-2889	human	abstract[160]|object[162]	new[160]|giv[162]	_	_
18-23	2890-2893	PCa	abstract[160]|object|object[162]	new[160]|giv|giv[162]	_	_
18-24	2894-2899	cells	abstract[160]|object[162]	new[160]|giv[162]	_	_
18-25	2900-2903	and	abstract[160]|object[162]	new[160]|giv[162]	_	_
18-26	2904-2907	its	abstract[160]|object[162]|abstract[163]	new[160]|giv[162]|giv[163]	_	_
18-27	2908-2916	clinical	abstract[160]|object[162]|abstract[163]	new[160]|giv[162]|giv[163]	_	_
18-28	2917-2929	applications	abstract[160]|object[162]|abstract[163]	new[160]|giv[162]|giv[163]	_	_
18-29	2930-2931	.	_	_	_	_
